Breaking News
Sort by:
Top Post
Almirall Appoints Mercedes Diz as VP, Corporate Strategy
Almirall, a global biopharmaceutical company focused on skin health, today announced that Mercedes Diz will […]
Abivax Appoints Ida Hatoum as Chief People Officer
Abivax SA, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the […]
Kallyope Appoints Franz Humer, Ph.D., as Chair of its Board of Directors
Kallyope, a clinical-stage biotechnology company discovering and developing novel, oral small-molecule therapeutics for diseases with […]
Marie Mazur Appointed Chair of PharmaJet Board of Directors
PharmaJet, a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals […]
CN Bio Appoints Dr. Samantha Macro as Chief Financial Officer
CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems […]
ENSEM Announces the Promotion of Shengfang Jin, PhD to President & Chief Executive Officer
Ensem Therapeutics, a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced the […]
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying […]
Visgenx Appoints William Pedranti as Chief Executive Officer
Visgenx, a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced […]
Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer
Affini-T Therapeutics, a precision immunotherapy company unlocking the power of T cells against oncogenic driver […]
GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia
GC Biopharma, a South Korean biopharmaceutical company, has announced that it has successfully obtained final […]
Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel Edwards as Chief Business Officer
Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more